Erasca Financial Results
Erasca reported third quarter 2026 financial results, highlighting a strong cash position of $948 million following an upsized $632.5 million public offering in July. The company received FDA Fast Track Designation for ERAS-0015 in metastatic pancreatic adenocarcinoma and is preparing to initiate three potentially registration-enabling trials in pancreatic and lung cancers starting in 2027.
- Term
- Q3 2026
“The emerging clinical profile of ERAS-0015 continues to support its potential as a foundational therapy across RAS-mutant cancers, both as a monotherapy and backbone for combination regimens.”
Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder
“With a strengthened balance sheet and experienced R&D leadership, we believe that we are positioned to execute our near-term milestones and advance programs addressing high unmet needs for patients with RAS-mutant cancers.”
Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder